Management of hypercholesterolemia in older persons for the prevention of cardiovascular disease

Cardiology in Review

Volumn 18, Issue 3, 2010, Pages 132-140

  Aronow, Wilbert S ^a   Frishman, William H ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Atherosclerotic vascular disease; Lipid lowering drugs; Lipids; Statins

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; CLOFIBRATE; EZETIMIBE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TIROFIBAN;

AGE DISTRIBUTION; AGING; ARTERY DISEASE; CARDIOVASCULAR DISEASE; CORONARY ARTERY DISEASE; DIET THERAPY; DRUG MECHANISM; GENDER; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; LIPID BLOOD LEVEL; MORBIDITY; MORTALITY; PRACTICE GUIDELINE; REVIEW; STROKE;

AGED; AGED, 80 AND OVER; ANTILIPEMIC AGENTS; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; COMBINED MODALITY THERAPY; DIET; EXERCISE; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; MALE;

EID: 77951463646     PISSN: 10615377     EISSN: None     Source Type: Journal    
DOI: 10.1097/CRD.0b013e3181c29571     Document Type: Review

References (121)

1. Castelli WP, Wilson PW, Levy D, et al. Cardiovascular disease in the elderly. Am J Cardiol. 1989;63:12H-19H.
2. Wong ND, Wilson PW, Kannel WB. Serum cholesterol as a prognostic factor after myocardial infarction: the Framingham Study. Ann Intern Med. 1991;115:687-693.
3. Benfante R, Reed D. Is elevated serum cholesterol level a factor for coronary heart disease in the elderly? JAMA. 1990;263:393-396.
4. Rubin SM, Sidney S, Black DM, et al. High blood cholesterol in elderly men and the excess risk for coronary heart disease. Ann Intern Med. 1990;113: 916-920.
5. Aronow WS, Ahn C. Risk factors for new coronary events in a large cohort of very elderly patients with and without coronary artery disease. Am J Cardiol. 1996;77:864-866.
6. Aronow WS, Ahn C. Correlation of serum lipids with the presence or absence of coronary artery disease in 1793 men and women aged 62 years. Am J Cardiol. 1994;73:702-703.
7. Corti MC, Guralnik JM, Salive ME, et al. HDL cholesterol predicts coronary heart disease mortality in older persons. JAMA. 1995;274:539-544.
8. Zimetbaum P, Frishman WH, Ooi WL, et al. Plasma lipids and lipoproteins and the incidence of cardiovascular disease in the very elderly: the Bronx Aging Study. Arterioscler Thromb. 1992;12:416-423.
9. Lavie CJ, Milani RV. National Cholesterol Education Program's recommendations, and implications of "missing" high-density lipoprotein cholesterol in cardiac rehabilitation programs. Am J Cardiol. 1991;68:1087.
10. Corti MC, Guralnik JM, Salive ME, et al. Clarifying the direct relation between total cholesterol levels and death from coronary heart disease in older persons. Ann Intern Med. 1997;126:753-760.
11. Reuben DB, Ix JH, Greendale GA, et al. The predictive value of combined hypoalbuminemia and hypocholesterolemia in high functioning communitydwelling older persons: MacArthur Studies of Successful Aging. J Am Geriatr Soc. 1999;47:402-406.
12. Ettinger WH, Sun WH, Brinkley N, et al. Interleukin-6 causes hypocholesterolemia in middle-aged and old rhesus monkeys. J Gerontol. 1995;50A: M137-M140.
13. Aronow WS, Ahn C. Correlation of serum lipids with the presence or absence of atherothrombotic brain infarction and peripheral arterial disease in 1834 men and women aged≥62 years. Am J Cardiol. 1994;73:995-997.
14. Suryadevara V, Storey SG, Aronow WS, et al. Association of abnormal serum lipids in elderly persons with atherosclerotic vascular disease and dementia, atherosclerotic vascular disease without dementia, dementia without atherosclerotic vascular disease, and no dementia or atherosclerotic vascular disease. J Gerontol Med Sci. 2003;58A:859-861. (Pubitemid 37221886)
15. Wolf PA. Cerebrovascular disease in the elderly. In: Tresch DD, Aronow WS, eds. Cardiovascular Disease in the Elderly Patient. New York, NY: Marcel Dekker, Inc; 1994:125-147.
16. Bihari-Varga M, Szekely J, Gruber E. Plasma high-density lipoproteins in coronary, cerebral and peripheral vascular disease: the influence of various risk factors. Atherosclerosis. 1981;40:337-345.
17. Pomrehn P, Duncan B, Weissfeld L, et al. The association of dyslipoproteinemia with symptoms and signs of peripheral arterial disease: the Lipid Research Clinics Program Prevalence Study. Circulation. 1986; 73(suppl I):I-100 -I-107.
18. Beach KW, Brunzell JD, Strandness DE Jr. Prevalence of severe arteriosclerosis obliterans in patients with diabetes mellitus: relation to smoking and form of therapy. Arteriosclerosis. 1982;2:275-280.
19. Aronow WS, Sales FF, Etienne F, et al. Prevalence of peripheral arterial disease and its correlation with risk factors for peripheral arterial disease in elderly patients in a long-term health care facility. Am J Cardiol. 1988;62: 644-646.
20. Buckley DA, Kelber ST, Goodwin JS. The use of dietary restrictions in malnourished nursing home patients. J Am Geriatr Soc. 1994;42:1100-1102.
21. Wilson MM, Vaswani S, Morley JE, et al. Prevalence and causes of undernutrition in medical outpatients. Am J Med. 1998;104:56-63.
22. Vanharanta M, Voutilainen S, Lakka TA, et al. Risk of acute coronary events according to serum concentrations of enterolactone: A prospective population-based case-control study. Lancet. 1999;354:2112-2115.
23. Ades PA, Poehlman ET. The effect of exercise training on serum lipids on the elderly. Am J Geriatr Cardiol. 1996;5:27-34.
24. American Heart Association. Older Americans and cardiovascular diseasesstatistics. 2004. Available at: http://www.americanheart.org/ downloadable/ heart/1136584495498OlderAm06.pdf. Accessed August 2008.
25. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
26. Miettinen TA, Pyorala K, Olsson AG, et al. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S). Circulation. 1997;96:4211-4218.
27. Pedersen TR, Kjekshus J, Pyorala K, et al. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian Simvastatin Survival Study (4S). Am J Cardiol. 1998;81:333-336.
28. Pedersen TR, Wilhelmsen L, Faergeman O, et al. Follow-up study of patients randomized in the Scandinavian Simvastatin Survival Study (4S) of cholesterol lowering. Am J Cardiol. 2000;86:257-262.
29. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001-1009.
30. Sacks FM, Moye LA, Davis BR, et al. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events Trial. Circulation. 1998;97: 1446-1452.
31. Lewis SJ, Sacks FM, Mitchell JS, et al. Effect of pravastatin on cardiovascular events in women after myocardial infarction: the cholesterol and recurrent events (CARE) trial. J Am Coll Cardiol. 1998;32:140-146.
32. Lewis SJ, Moye LA, Sacks FM, et al. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range: results of the cholesterol and recurrent events (CARE) trial. Ann Intern Med. 1998;129:681-689.
33. Plehn JF, Davis BR, Sacks FM, et al. Reduction of stroke incidence after myocardial infarction with pravastatin: the cholesterol and recurrent events (CARE) study. Circulation. 1999;99:216-223.
34. The Long-Term Intervention With Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349-1357.
35. The LIPID Study Group. Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up. Lancet. 2002;359:1379-1387.
36. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet. 2002;360:7-22.
37. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
38. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial. Lancet. 2002;360:1623-1630.
39. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study: A randomized controlled trial. JAMA. 2001;285:1711-1718.
40. Aronow WS, Nayak D, Woodworth S, et al. Effect of simvastatin versus placebo on treadmill exercise time until the onset of intermittent claudication in older patients with peripheral arterial disease at six months and at one year after treatment. Am J Cardiol. 2003;92:711-712.
41. Mohler ER III, Hiatt WR, Creager MA; for the Study Investigators. Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation. 2003;108:1481-1486.
42. Mondillo S, Ballo P, Barbati R, et al. Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascular disease. Am J Med. 2003;114:359-364.
43. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial. Lancet. 2003;361:1149-1158. (Pubitemid 36398384)
44. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes mellitus in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomized placebo-controlled trial. Lancet. 2004;364:685-696.
45. Hitman GA, Colhoun H, Newman C, et al. on behalf of the CARDS investigators:Stroke prediction and stroke prevention with atorvastatin in the Collaborative Atorvastatin Diabetes Study (CARDS). Diabet Med. 2007;24: 1313-1321.
46. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: A randomized controlled trial. JAMA. 2004;291:1071-1080. (Pubitemid 38541684)
47. Cannon CP, Braunwald E, McCabe CH, et al. Comparison of intensive and moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495-1504. (Pubitemid 38477774)
48. Murphy SA, Cannon CP, Wiviott SD, et al. Effect of intensive lipidlowering therapy on mortality after acute coronary syndrome (a patient analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trials). Am J Cardiol. 2007;100:1047-1051.
49. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Eng J Med. 2005; 352:1425-1435.
50. Waters DD, LaRosa JC, Barter P, et al. Effects of high-dose atorvastatin on cerebrovascular events in patients with stable coronary disease in the TNT (treating to new targets) study. J Am Coll Cardiol. 2006;48:1793-1799.
51. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267-1278.
52. Deedwania P, Stone PH, Merz CN, et al. Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE). Circulation. 2007;115:700-707.
53. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators: high-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355:549-559.
54. Amarenco P, Goldstein LB, Szarek M, et al. Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trial. Stroke. 2007;38:3198-3204.
55. Chaturvedi S, Zivin J, Breazna A, et al; for the SPARCL investigators. Effect of atorvastatin in elderly patients with a recent stroke or transient ischemic attack. Neurology. 2009;72:688-694.
56. Goldstein LB, Amarenco P, Szarek M, et al. on behalf of the SPARCL investigators: hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study. Neurology. 2008;70:2364-2370.
57. Sacco RL, Chong JY, Elkind MS, et al. Experimental treatments for acute ischaemic stroke. Lancet. 2007;369:331-341.
58. Montaner J, Chacon P, Krupinski J, et al. Simvastatin in the acute phase of ischemic stroke: A safety and efficacy pilot trial. Eur J Neurol. 2008;15:82-90.
59. Elkind MS, Sacco RL, MacArthur RB, et al. High-dose lovastatin for acute ischemic stroke: results of the phase 1 dose escalation Neuroprotection with Statin Therapy for Acute Recovery Trial (NeuSTART). Cerebrovasc Dis. 2009;28:266-275.
60. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA. 1998;279:1615-1622.
61. Ridker PM, Danielson E, Francisco MI, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-2207.
62. Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA. 1975;231:360-381.
63. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986;8:1245-1255.
64. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Eng J Med. 1999;341:410-418.
65. Aronow WS, Ahn C. Incidence of new coronary events in older persons with prior myocardial infarction and serum low-density lipoprotein cholesterol ≥ 125 mg/dL treated with statins versus no lipid-lowering drug. Am J Cardiol. 2002;89:67-69. (Pubitemid 34066591)
66. Aronow WS, Ahn C, Gutstein H. Incidence of new atherothrombotic brain infarction in older persons with prior myocardial infarction and serum low-density lipoprotein cholesterol ≥ 125 mg/dL treated with statins versus no lipid-lowering drug. J Gerontol Med Sci. 2002;57A:M333-M335. (Pubitemid 34464975)
67. Aronow WS, Ahn C. Frequency of congestive heart failure in older persons with prior myocardial infarction and serum low-density lipoprotein cholesterol ≥ 125 mg/dL treated with statins versus no lipid-lowering drug. Am J Cardiol. 2002;90:147-149. (Pubitemid 34775124)
68. Aronow WS, Ahn C. Reduction of coronary events with aspirin in older patients with prior myocardial infarction treated with and without statins. Heart Disease. 2002;4:159-161.
69. Aronow WS, Ahn C, Gutstein H. Reduction of new coronary events and of new atherothrombotic brain infarction in older persons with diabetes mellitus, prior myocardial infarction, and serum low-density lipoprotein cholesterol ≥ 125 mg/dL treated with statins. J Gerontol Med Sci. 2002;57A: M747-M750. (Pubitemid 35340556)
70. Pedersen TR, Faergeman O, Kastelein JJ, et al. High-dose atorvastatin vs. usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: A randomized controlled trial. JAMA. 2005;294:2437-2445.
71. Aronow WS, Ahn C. Frequency of new coronary events in older persons with peripheral arterial disease and serum low-density lipoprotein cholesterol ≥ 125 mg/dL treated with statins versus no lipid-lowering drug. Am J Cardiol. 2002;90:789-791. (Pubitemid 35279409)
72. Ravipati G, Aronow WS, Ahn C, et al. Incidence of new stroke or new myocardial infarction or death in patients with severe carotid arterial disease treated with and without statins. Am J Cardiol. 2006;98:1170-1171.
73. Sukhija R, Aronow WS, Sandhu R, et al. Mortality and size of abdominal aortic aneurysm at long-term follow-up of patients not treated surgically and treated with and without statins. Am J Cardiol. 2006;97:279-280.
74. Sukhija R, Bursac Z, Kakar P, et al. Effect of statins on the development of renal dysfunction. Am J Cardiol. 2008;101:975-979.
75. Aronow WS, Ahn C, Kronzon I, et al. Association of coronary risk factors and use of statins with progression of mild valvular aortic stenosis in older persons. Am J Cardiol. 2001;88:693-695. (Pubitemid 32831111)
76. Novaro GM, Tiong IY, Pearce GL, et al. Effect of hydroxymethylglutaryl coenzyme A reductase inhibitors on the progression of calcific aortic stenosis. Circulation. 2001;104:2205-2209.
77. Bellamy MF, Pellikka PA, Klarich KW, et al. Association of cholesterol levels, hydroxymethylglutaryl coenzyme-A reductase inhibitor treatment, and progression of aortic stenosis in the community. J Am Coll Cardiol. 2002;40:1723-1730.
78. Moura LM, Ramos SF, Zamorano JL, et al. Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis. J Am Coll Cardiol. 2007;49:554-561.
79. Cowell SJ, Newby DE, Preston RJ, et al. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med. 2005;352: 2389-2397.
80. Rossebo AB, Pedersen TR, Boman K, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med. 2008;359:1343-1356.
81. Horwich TB, MacLellan WR, Fonarow GC. Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure. J Am Coll Cardiol. 2004;43:642-648.
82. Foody JM, Shah R, Galusha D, et al. Statins and mortality among elderly patients hospitalized with heart failure. Circulation. 2006;113:1086-1092.
83. GISSI-HF Investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): A randomized, double-blind, placebo-controlled trial. Lancet. 2008;372:1231-1239.
84. Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006;295:156-1565.
85. Ballantyne CM, Raichlen JS, Nicholls SJ, et al. Effect of rosuvastatin therapy on coronary artery stenoses assessed by quantitative coronary angiography: A study to evaluate the effect of rosuvastatin on intravascular ultrasound-derived coronary atheroma burden. Circulation. 2008;117:2458-2466.
86. Hiro T, Kimura T, Morimoto T, et al. Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: A multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS-Japan Assessment of pitavastatin and atorvastatin in acute coronary syndrome- study). J Am Coll Cardiol. 2009;54:293-302.
87. De Sutter J, Tavernier R, De Buyzere M, et al. Lipid lowering drugs and recurrences of life-threatening ventricular arrhythmias in high-risk patients. J Am Coll Cardiol. 2000;36:766-772.
88. Mitchell LB, Powell JL, Gillis AM, et al. Are lipid-lowering drugs also antiarrhythmic drugs? An analysis of the antiarrhythmics versus implantable defibrillators (AVID) trial. J Am Coll Cardiol. 2003;42:81-87.
89. Chiu JH, Abdelhadi RH, Chung MK, et al. Effect of statin therapy on risk of ventricular arrhythmia among patients with coronary artery disease and an implantable cardioverter-defibrillator. Am J Cardiol. 2005;95:490-491.
90. Vyas AK, Guo H, Moss AJ, et al. Reduction in ventricular tachyarrhythmias with statins in the Multicenter automatic Defibrillator Implantation trial (MADIT)-II. J Am Coll Cardiol. 2006;47:769-773.
91. Lai HM, Aronow WS, Kruger A, et al. Effect of beta blockers, angiotensinconverting enzyme inhibitors or angiotensin receptor blockers, and statins on mortality in patients with implantable cardioverter-defibrillators. Am J Cardiol. 2008;102:77-78.
92. Desai H, Aronow WS, Tsai FS, et al. Statins reduce appropriate cardioverter-defibrillator shocks and mortality in patients with heart failure and combined cardiac resynchronization and implantantable cardioverter- defibrillator therapy. J Cardiovasc Pharmacol Ther. 2009;14:176-179.
93. Durazzo AE, Machado FS, Ikeoka DT, et al. Reduction in cardiovascular events after vascular surgery with atorvastatin: A randomized trial. J Vasc Surg. 2004;39:967-976.
94. Kertai MD, Boersma E, Westerhout CM, et al. Association between longterm statin use and mortality after successful abdominal aortic aneurysm surgery. Am J Med. 2004;116:96-103.
95. Poldermans D, Bax JJ, Kertai MD, et al. Statins are associated with a reduced incidence of perioperative mortality in patients undergoing major noncardiac vascular surgery. Circulation. 2003;107:1848-1851.
96. O'Neil-Callahan K, Katsimaglia MR, Ryan J, et al. Statins decrease perioperative cardiac complications in patients undergoing noncardiac vascular surgery: the statins for risk reduction in surgery (StaRRS) study. J Am Coll Cardiol. 2005;45:336-342.
97. Aronow WS, Desai H, Ahn C, et al. Incidence of perioperative myocardial infarction and 2-year mortality in patients who underwent noncardiac vascular surgery treated with and without statins (abstract). Circulation. 2009;120(suppl):S448.
98. Jick H, Zomberg GL, Jick SS, et al. Statins and the risk of dementia. Lancet. 2000;356:1627-1631.
99. Rockwood K, Kirkland S, Hogan DB, et al. Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch Neurol. 2002;59:223-227.
100. Trompet S, van Vliet P, de Craen AJ, et al. Pravastatin and cognitive function in the elderly: results of the PROSPER study. J Neurol. In press.
101. Pitt B, Mancini GB, Ellis SG, et al. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. J Am Coll Cardiol. 1995;26:1133-1139.
102. Tamura A, Mikuriya Y, Nasu M; the Coronary Artery Regression Study (CARS) Group. Effect of pravastatin (10 mg/day) on progression of coronary atherosclerosis in patients with serum total cholesterol levels from 160 to 220 mg/dL and angiographically documented coronary artery disease. Am J Cardiol. 1997;79:893-896.
103. The Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and lowdose anticoagulation on obstructive changes in saphenous-vein coronaryartery bypass grafts. N Engl J Med. 1997;336:153-162.
104. Vaughan CJ, Gotto AM Jr, Basson CT. The evolving role of statins in the management of atherosclerosis. J Am Coll Cardiol. 2000;35:1-10.
105. Anderson TJ, Meredith IT, Yeung AC, et al. The effect of cholesterollowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med. 1995;332:488-493.
106. Dupuis J, Tardif JC, Cernacek P, et al. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes: the RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial. Circulation. 1999;99:3227-3233.
107. Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA. 1998;279:1643-1650.
108. Andrews TC, Raby K, Barry J, et al. Effect of cholesterol reduction on myocardial ischemia in patients with coronary disease. Circulation. 1997; 95:324-328.
109. van Boven AJ, Jukema JW, Zwinderman AH, et al. Reduction of transient myocardial ischemia with pravastatin in addition to the conventional treatment in patients with angina pectoris. Circulation. 1996;94:1503-1505.
110. Ridker PM, Rifai N, Pfeffer MA, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation. 1998;98:839-844.
111. Amarenco P, Labreuche J, Lavallée P, et al. Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis. Stroke. 2004;35:2902-2909.
112. Sironi L, Cimino M, Guerrini U, et al. Treatment with statins after induction of focal ischemia in rats reduces the extent of brain damage. Arterioscler Thromb Vasc Biol. 2003;23:322-327.
113. Chen J, Zhang ZG, Li Y, et al. Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke. Ann Neurol. 2003;53:743-751.
114. Zhang L, Zhang ZG, Ding GL, et al. Multitargeted effects of statin-enhanced thrombolytic therapy for stroke with recombinant human tissue-type plasminogen activator in the rat. Circulation. 2005;29:3486-3494.
115. Aronow WS. Should the NCEP III guidelines be changed in elderly and younger persons at high risk for cardiovascular events? J Gerontol Med Sci. 2005;60A:M591-M592.
116. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227-239.
117. Warshafsky S, Packard D, Marks SJ, et al. Efficacy of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors for prevention of stroke. J Gen Intern Med. 1999;14:763-774
118. Vergouwen MD, de Haan RJ, Vermeulen M, et al. Statin treatment and the occurrence of hemorrhagic stroke in patients with a history of cerebrovascular disease. Stroke. 2008;39:497-502.
119. Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR trial). Am J Cardiol. 2003;92:152-160.
120. Gagne C, Gaudet D, Bruckert E; for the Ezetimibe Study Group. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation. 2002; 105:2469-2475.
121. Prueksaritanont T, Tang C, Qiu Y, et al. Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metab Dispos. 2002;30:1280-1287.